Compare ADMA Biologics Inc (ADMA) vs Becton Dickinson and Co (BDX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Becton Dickinson and Co — how do they compare? ADMA Biologics Inc trades at $9.23 (market cap $2.13B), while Becton Dickinson and Co trades at $151.96 (market cap $43.07B). The key difference: Becton Dickinson and Co is far larger — about 20.2× ADMA Biologics Inc's market cap, and Becton Dickinson and Co pays a 2.69% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | BDX | |
|---|---|---|
Market Cap | $2.13B | $43.07B |
Sector | Health | Health |
52-Week High | $20.38 | $185.39 |
52-Week Low | $7.60 | $135.49 |
Enterprise Value | $2.20B | $59.53B |
Dividend Yield | — | 2.69% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
BDX trades at $156.30, down 1.13% today, with a bullish technical signal from moving averages but neutral oscillators. Recent earnings beat expectations for Q1 2026, and the company maintains stable revenue growth, reaching $21.84B in 2025. Positive news highlights innovation in medical technology and dividend reliability, supporting a mixed but leaning positive analyst view.
Outlook is cautiously optimistic with a consensus price target of $172.33 offering ~10% upside. Risks include hospital spending caution and reimbursement uncertainty, but strong cash flow and product launches provide growth catalysts. The stock presents a balanced opportunity for dividend-focused investors amid moderate volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →
